Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy

Biomedicine and Pharmacotherapy

Volumn 95, Issue , 2017, Pages 731-742

  Valedkarimi, Zahra ^a,b   Nasiri, Hadi ^a,b   Aghebati Maleki, Leili ^a,b   Majidi, Jafar ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antibody cytokine fusion proteins; Cancer; Immunotherapy; Monoclonal antibody

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; IMMUNOCYTOKINE; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; CYTOKINE; FUSION PROTEIN;

CANCER GENE THERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CLINICAL STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; REVIEW; ANIMAL; BIOLOGICAL MODEL; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; TREATMENT OUTCOME;

ANIMALS; CYTOKINES; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 85028946292     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2017.07.160     Document Type: Review

References (170)

1. Conniot, J., Silva, J.M., Fernandes, J.G., Silva, L.C., Gaspar, R., Brocchini, S., Florindo, H.F., Barata, T.S., Cancer Immunotherapy: Nanodelivery Approaches for Immune Cell Targeting and Tracking, Cancer Nanotheranostics: What Have We Learned So Far?. 2016, 68.
2. Vacchelli, E., Aranda, F., Obrist, F., Eggermont, A., Galon, J., Cremer, I., Zitvogel, L., Kroemer, G., Galluzzi, L., Trial watch: immunostimulatory cytokines in cancer therapy. Oncoimmunology, 3(6), 2014, e29030.
3. Kelso, A., Cytokines: principles and prospects. Immunol. Cell Biol. 76:4 (1998), 300–317.
4. Haddad, J.J., Cytokines and related receptor-mediated signaling pathways. Biochem. Biophys. Res. Commun. 297:4 (2002), 700–713.
5. Baxevanis, C.N., Perez, S.A., Papamichail, M., Cancer immunotherapy. Crit. Rev. Clin. Lab. Sci. 46:4 (2009), 167–189.
6. Rosenberg, S.A., IL-2: the first effective immunotherapy for human cancer. J. Immunol. 192:12 (2014), 5451–5458.
7. Shaker, M.A., Younes, H.M., Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy. J. Pharm. Sci. 98:7 (2009), 2268–2298.
8. Clement, J.M., McDermott, D.F., The high-dose aldesleukin (IL-2)select trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma. Clin. Genitourin. Cancer 7:2 (2009), E7–E9.
9. Diamantis, N., Banerji, U., Antibody-drug conjugates—an emerging class of cancer treatment. Br. J. Cancer, 114, 2016, 362.
10. Kontermann, R.E., Antibody–cytokine fusion proteins. Arch. Biochem. Biophys. 526:2 (2012), 194–205.
11. Young, P.A., Morrison, S.L., Timmerman, J.M., Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety. Semin. Oncol., 2014, 623–636 Elsevier.
12. Harvill, E.T., Morrison, S.L., An IgG3-IL2 fusion protein activates complement, binds FcγRI, generates LAK activity and shows enhanced binding to the high affinity IL-2R. Immunotechnology 1:2 (1995), 95–105.
13. Hornick, J.L., Khawli, L.A., Hu, P., Lynch, M., Anderson, P.M., Epstein, A.L., Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties. Blood 89:12 (1997), 4437–4447.
14. Gillies, S.D., Lan, Y., Wesolowski, J.S., Qian, X., Reisfeld, R.A., Holden, S., Super, M., Lo, K.-M., Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. J. Immunol. 160:12 (1998), 6195–6203.
15. Lode, H.N., Xiang, R., Becker, J.C., Gillies, S.D., Reisfeld, R.A., Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol. Ther. 80:3 (1998), 277–292.
16. Penichet, M., Shin, S., Morrison, S., Fab Fusion Proteins: Immunoligands. 1999, John Wiley & Son, New York, NY, 15–52.
17. Penichet, M.L., Morrison, S.L., Antibody–cytokine fusion proteins for the therapy of cancer. J. Immunol. Methods 248:1 (2001), 91–101.
18. Sondel, P.M., Hank, J.A., Antibody-directed, effector cell-mediated tumor destruction. Hematol. Oncol. Clin. 15:4 (2001), 703–721.
19. Müller, D., Antibody–cytokine fusion proteins for cancer immunotherapy: an update on recent developments. BioDrugs 28:2 (2014), 123–131.
20. Maleki, L.A., Baradaran, B., Majidi, J., Mohammadian, M., Shahneh, F.Z., Future prospects of monoclonal antibodies as magic bullets in immunotherapy. Hum. Antibodies 22:1-2 (2013), 9–13.
21. Müller, D., Kontermann, R.E., Bispecific antibodies for cancer immunotherapy. BioDrugs 24:2 (2010), 89–98.
22. Aghebati-Maleki, L., Shabani, M., Baradaran, B., Motallebnezhad, M., Majidi, J., Yousefi, M., Receptor tyrosine kinase-like orphan receptor 1 (ROR-1): an emerging target for diagnosis and therapy of chronic lymphocytic leukemia. Biomed. Pharmacother. 88 (2017), 814–822.
23. Aghebati-Maleki, L., Bakhshinejad, B., Baradaran, B., Motallebnezhad, M., Aghebati-Maleki, A., Nickho, H., Yousefi, M., Majidi, J., Phage display as a promising approach for vaccine development. J. Biomed. Sci., 23(1), 2016, 66.
24. Yuraszeck, T., Kasichayanula, S., Benjamin, J.E., Translation and clinical development of bispecific T cell engaging antibodies for cancer treatment. Clin. Pharmacol. Ther. 101 (2017), 634–645.
25. Maleki, L.A., Majidi, J., Baradaran, B., Abdolalizadeh, J., Akbari, A.M., Production and characterization of murine monoclonal antibody against synthetic peptide of CD34. Hum. Antibodies 22:1–2 (2013), 1–8.
26. Vacchelli, E., Eggermont, A., Fridman, W.H., Galon, J., Zitvogel, L., Kroemer, G., Galluzzi, L., Trial watch: immunostimulatory cytokines. Oncoimmunology, 2(7), 2013, e24850.
27. Ceeraz, S., Nowak, E.C., Noelle, R.J., B7 family checkpoint regulators in immune regulation and disease. Trends Immunol. 34:11 (2013), 556–563.
28. Croft, M., Benedict, C.A., Ware, C.F., Clinical targeting of the TNF and TNFR superfamilies. Nat. Rev. Drug Discov. 12:2 (2013), 147–168.
29. Kiefer, J.D., Neri, D., Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site. Immunol. Rev. 270:1 (2016), 178–192.
30. Ghasemi, R., Lazear, E., Wang, X., Arefanian, S., Zheleznyak, A., Carreno, B.M., Higashikubo, R., Gelman, A.E., Kreisel, D., Fremont, D.H., Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy. Nat. Commun., 7, 2016.
31. Lode, H.N., Reisfeld, R.A., Targeted cytokines for cancer immunotherapy. Immunol. Res. 21:2–3 (2000), 279–288.
32. Davis, C.B., Gillies, S.D., Immunocytokines: amplification of anti-cancer immunity, Cancer Immunology. Immunotherapy 52:5 (2003), 297–308.
33. Cruz, J.D., Huang, T., Penichet, M., Morrison, S., Antibody-cytokine fusion proteins: innovative weapons in the war against cancer. Clin. Exp. Med. 4:2 (2004), 57–64.
34. Schrama, D., Reisfeld, R.A., Becker, J.C., Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov. 5:2 (2006), 147–159.
35. Ortiz-Sánchez, E., Helguera, G., Daniels, T.R., Penichet, M.L., Antibody–cytokine fusion proteins: applications in cancer therapy. Expert Opin. Biol. Ther. 8:5 (2008), 609–632.
36. Aggarwal, B.B., Gupta, S.C., Kim, J.H., Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 119:3 (2012), 651–665.
37. Kalliolias, G.D., Ivashkiv, L.B., TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat. Rev. Rheumatol. 12:1 (2016), 49–62.
38. Fischer, R., Kontermann, R.E., Maier, O., Targeting sTNF/TNFR1 signaling as a new therapeutic strategy. Antibodies 4:1 (2015), 48–70.
39. Dolman, C.S., Mueller, B.M., Lode, H.N., Xiang, R., Gillies, S.D., Reisfeld, R.A., Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy. Clin. Cancer Res. 4:10 (1998), 2551–2557.
40. Johnson, E.E., Lum, H.D., Rakhmilevich, A.L., Schmidt, B.E., Furlong, M., Buhtoiarov, I.N., Hank, J.A., Raubitschek, A., Colcher, D., Reisfeld, R.A., Intratumoral immunocytokine treatment results in enhanced antitumor effects. Cancer Immunol. Immunother. 57:12 (2008), 1891–1902.
41. C. Gerdes, C. Klein, V.G. Nicolini, P. Umana, Combination IL-2 immunoconjugate therapy, Google Patents, 2016.
42. J.A. Ledbetter, M.S. Hayden-Ledbetter, Binding domain-immunoglobulin fusion proteins, Google Patents, 2015.
43. Kontermann, R.E., Brinkmann, U., Bispecific antibodies. Drug Discov. Today 20:7 (2015), 838–847.
44. Aghebati Maleki, L., Majidi, J., Baradaran, B., Abdolalizadeh, J., Kazemi, T., Aghebati Maleki, A., Sineh Sepehr, K., Large scale generation and characterization of anti-human CD34 monoclonal antibody in ascetic fluid of Balb/c mice. Adv. Pharm. Bull. 3:1 (2013), 211–216.
45. Aghebati-Maleki, L., Younesi, V., Baradaran, B., Abdolalizadeh, J., Motallebnezhad, M., Nickho, H., Shanehbandi, D., Majidi, J., Yousefi, M., Antiproliferative and apoptotic effects of novel anti-ROR1 single-chain antibodies in hematological malignancies. SLAS Discov. 22:4 (2017), 408–417.
46. Beckman, R., Weiner, L., Davis, H., Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer, 109(2), 2007, 170.
47. Peng, L.S., Penichet, M.L., Morrison, S.L., A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J. Immunol. 163:1 (1999), 250–258.
48. Pasche, N., Neri, D., Immunocytokines: a novel class of potent armed antibodies. Drug Discovery Today 17:11 (2012), 583–590.
49. Krippner-Heidenreich, A., Grunwald, I., Zimmermann, G., Kühnle, M., Gerspach, J., Sterns, T., Shnyder, S.D., Gill, J.H., Männel, D.N., Pfizenmaier, K., Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity. J. Immunol. 180:12 (2008), 8176–8183.
50. Niesner, U., Halin, C., Lozzi, L., Günthert, M., Neri, P., Wunderli-Allenspach, H., Zardi, L., Neri, D., Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjugate Chem., 13(4), 2002, 729.
51. Melkko, S., Halin, C., Borsi, L., Zardi, L., Neri, D., An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance. Int. J. Radiat. Oncol.* Biol.* Phys. 54:5 (2002), 1485–1490.
52. Halin, C., Niesner, U., Villani, M., Zardi, L., Neri, D., Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins. Int. J. Cancer J. international du cancer 102:2 (2002), 109–116.
53. Hemmerle, T., Wulhfard, S., Neri, D., A critical evaluation of the tumor-targeting properties of bispecific antibodies based on quantitative biodistribution data. Protein Eng. Des. Sel., 2012 gzs061.
54. Gafner, V., Trachsel, E., Neri, D., An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Int. J. Cancer Journal International du cancer 119:9 (2006), 2205–2212.
55. Ebbinghaus, C., Ronca, R., Kaspar, M., Grabulovski, D., Berndt, A., Kosmehl, H., Zardi, L., Neri, D., Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int. J. Cancer Journal international du cancer 116:2 (2005), 304–313.
56. Pestka, S., Krause, C.D., Walter, M.R., Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202:1 (2004), 8–32.
57. Naramura, M., Gillies, S.D., Mendelsohn, J., Reisfeld, R.A., Mueller, B.M., Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells. Immunol. Lett. 39:1 (1993), 91–99.
58. Alderson, K.L., Sondel, P.M., Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J. Biomed. Biotechnol., 2011, 2011.
59. Walter, M.R., Cook, W.J., Ealick, S.E., Nagabhushan, T.L., Trotta, P.P., Bugg, C.E., Three-dimensional structure of recombinant human granulocyte-macrophage colony-stimulating factor. J. Mol. Biol. 24:4 (1992), 1075–1085.
60. Singhal, S., Bhojnagarwala, P.S., O'Brien, S., Moon, E.K., Garfall, A.L., Rao, A.S., Quatromoni, J.G., Stephen, T.L., Litzky, L., Deshpande, C., Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer. Cancer Cell 30:1 (2016), 120–135.
61. Fischer, H., Frosch, S., Reske, K., Reske-Kunz, A., Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J. Immunol. 141:11 (1988), 3882–3888.
62. Heufler, C., Koch, F., Schuler, G., Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J. Exp. Med. 167:2 (1988), 700–705.
63. Morrissey, P., Bressler, L., Park, L., Alpert, A., Gillis, S., Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J. Immunol. 139:4 (1987), 1113–1119.
64. Smith, P.D., Lamerson, C.L., Wong, H.L., Wahl, L.M., Wahl, S.M., Granulocyte-macrophage colony-stimulating factor stimulates human monocyte accessory cell function. J. Immunol. 144:10 (1990), 3829–3834.
65. Steis, R.G., VanderMolen, L.A., Longo, D.L., Clark, J.W., Smith, J.W., Kopp, W.C., Ruscetti, F.W., Creekmore, S.P., Elwood, L.J., Hursey, J., Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial. J. Natl. Cancer Inst. 82:8 (1990), 697–703.
66. Arnaout, M., Wang, E., Clark, S., Sieff, C., Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J. Clin. Invest., 78(2), 1986, 597.
67. Lisak, R.P., Bealmear, B., Benjamins, J.A., Schwann cell differentiation inhibits interferon-gamma induction of expression of major histocompatibility complex class II and intercellular adhesion molecule-1. J. Neuroimmunol. 295 (2016), 93–99.
68. Santoli, D., Clark, S., Kreider, B., Maslin, P., Rovera, G., Amplification of IL-2-driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor. J. Immunol. 41:2 (1988), 519–526.
69. Shi, Y., Liu, C.H., Roberts, A.I., Das, J., Xu, G., Ren, G., Zhang, Y., Zhang, L., Yuan, Z.R., Tan, H.S.W., Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res. 16:2 (2006), 126–133.
70. Miguel, A., Herrero, M., Sendra, L., Botella, R., Algás, R., Sánchez, M., Aliño, S., Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+ IL-12 genetically modified tumor cell vaccines. Cancer Gene Ther. 20:10 (2013), 576–581.
71. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., Mulligan, R.C., Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. 90:8 (1993), 3539–3543.
72. Jäger, E., Ringhoffer, M., Dienes, H.P., Arand, M., Karbach, J., Jäger, D., Ilsemann, C., Hagedorn, M., Oesch, F., Knuth, A., Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer 67:1 (1996), 54–62.
73. Ruef, C., Coleman, D.L., Granulocyte-macrophage colony-stimulating factor: pleiotropic cytokine with potential clinical usefulness. Rev. Infect. Dis. 12:1 (1990), 41–62.
74. Daniels, T.R., Delgado, T., Rodriguez, J.A., Helguera, G., Penichet, M.L., The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 121:2 (2006), 144–158.
75. Dreier, T., Lode, H.N., Xiang, R., Dolman, C.S., Reisfeld, R.A., Kang, A.S., Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities. Bioconjugate Chem. 9:4 (1998), 482–489.
76. Batova, A., Kamps, A., Gillies, S.D., Reisfeld, R.A., Alice, L.Y., The Ch14. 18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. Clin. Cancer Res. 5:12 (1999), 4259–4263.
77. Metelitsa, L., Gillies, S., Super, M., Shimada, H., Reynolds, C., Seeger, R., Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis. Blood 99:11 (2002), 4166–4173.
78. Epstein, A.L., Marder, R.J., Winter, J.N., Stathopoulos, E., Chen, F.-M., Parker, J.W., Taylor, C.R., Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res. 47:3 (1987), 830–840.
79. Albrecht, H., DeNardo, S.J., Update: recombinant antibodies: from the laboratory to the clinic. Cancer Biother. Radiopharm. 21:4 (2006), 285–304.
80. Wu, A.M., Senter, P.D., Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 3:9 (2005), 1137–1146.
81. Kaspar, M., Trachsel, E., Neri, D., The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res. 67:10 (2007), 4940–4948.
82. Boyman, O., Sprent, J., The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12:3 (2012), 180–190.
83. Benczik, M., Gaffen, S.L., The interleukin (IL)-2 family cytokines: survival and proliferation signaling pathways in T lymphocytes. Immunol. Invest. 33:2 (2004), 109–142.
84. Malek, T.R., Castro, I., Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 33:2 (2010), 153–165.
85. Rosenberg, S.A., Lotze, M.T., Muul, L.M., Leitman, S., Chang, A.E., Ettinghausen, S.E., Matory, Y.L., Skibber, J.M., Shiloni, E., Vetto, J.T., Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New Engl. J. Med. 313:23 (1985), 1485–1492.
86. Gillies, S.D., Lo, K.-M., Burger, C., Lan, Y., Dahl, T., Wong, W.-K., Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis. Clin. Cancer Res. 8:1 (2002), 210–216.
87. Anderson, K.C., Bates, M.P., Slaughenhoupt, B.L., Pinkus, G.S., Schlossman, S.F., Nadler, L.M., Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63:6 (1984), 1424–1433.
88. Delgado, J., Matutes, E., Morilla, A.M., Morilla, R.M., Owusu-Ankomah, K.A., Rafiq-Mohammed, F., Del Giudice, I., Catovsky, D., Diagnostic significance of CD20 and FMC7 expression in B-cell disorders. Am. J. Clin. Pathol. 120:5 (2003), 754–759.
89. Gillies, S.D., Lan, Y., Williams, S., Carr, F., Forman, S., Raubitschek, A., Lo, K.-M., An anti-CD20–IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood 105:10 (2005), 3972–3978.
90. Poczatek, R.B., Myers, R.B., Manne, U., Oelschlager, D.K., Weiss, H.L., Bostwick, D.G., Grizzle, W.E., Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J. Urol. 162:4 (1999), 1462–1466.
91. Pauli, C., Münz, M., Kieu, C., Mack, B., Breinl, P., Wollenberg, B., Lang, S., Zeidler, R., Gires, O., Tumor-specific glycosylation of the carcinoma-associated epithelial cell adhesion molecule EpCAM in head and neck carcinomas. Cancer Lett. 193:1 (2003), 25–32.
92. Shetye, J., Christensson, B., Rubio, C., Rodensjö, M., Biberfeld, P., Mellstedt, H., The tumor-associated antigens BR55-2, GA73-3 and GICA 19-9 in normal and corresponding neoplastic human tissues, especially gastrointestinal tissues. Anticancer Res. 9:2 (1988), 395–404.
93. Osta, W.A., Chen, Y., Mikhitarian, K., Mitas, M., Salem, M., Hannun, Y.A., Cole, D.J., Gillanders, W.E., EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 64:16 (2004), 5818–5824.
94. de Boer, C.J., van Krieken, J.H., Janssen-van Rhijn, C.M., Litvinov, S.V., Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J. Pathol. 188:2 (1999), 201–206.
95. Xiang, R., Lode, H.N., Dolman, C.S., Dreier, T., Varki, N.M., Qian, X., Lo, K.-M., Lan, Y., Super, M., Gillies, S.D., Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res. 57:21 (1997), 4948–4955.
96. Xiang, R., Lode, H.N., Gillies, S.D., Reisfeld, R.A., T cell memory against colon carcinoma is long-lived in the absence of antigen. J. Immunol. 163:7 (1999), 3676–3683.
97. Imboden, M., Murphy, K.R., Rakhmilevich, A.L., Neal, Z.C., Xiang, R., Reisfeld, R.A., Gillies, S.D., Sondel, P.M., The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res. 61:4 (2001), 1500–1507.
98. Ruehlmann, J.M., Xiang, R., Niethammer, A.G., Ba, Y., Pertl, U., Dolman, C.S., Gillies, S.D., Reisfeld, R.A., MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res. 61:23 (2001), 8498–8503.
99. Holden, S.A., Lan, Y., Pardo, A.M., Wesolowski, J.S., Gillies, S.D., Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. Clin. Cancer Res. 7:9 (2001), 2862–2869.
100. Cheresh, D.A., Pierschbacher, M.D., Herzig, M.A., Mujoo, K., Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J. Cell Biol. 102:3 (1986), 688–696.
101. Kendra, K., Gan, J., Ricci, M., Surfus, J., Shaker, A., Super, M., Frost, J.D., Rakhmilevich, A., Hank, J.A., Gillies, S.D., Pharmacokinetics and stability of the ch14. 18–interleukin-2 fusion protein in mice. Cancer Immunol. Immunother. 48:5 (1999), 219–229.
102. Neal, Z.C., Yang, J.C., Rakhmilevich, A.L., Buhtoiarov, I.N., Lum, H.E., Imboden, M., Hank, J.A., Lode, H.N., Reisfeld, R.A., Gillies, S.D., Enhanced activity of hu14. 18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin. Cancer Res. 10:14 (2004), 4839–4847.
103. Becker, J.C., Pancook, J.D., Gillies, S.D., Furukawa, K., Reisfeld, R.A., T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J. Exp. Med. 183:5 (1996), 2361–2366.
104. Becker, J.C., Varki, N., Gillies, S.D., Furukawa, K., Reisfeld, R.A., An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc. Natl. Acad. Sci. 93:15 (1996), 7826–7831.
105. Becker, J.C., Varki, N., Gillies, S.D., Furukawa, K., Reisfeld, R.A., Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J. Clin. Invest., 98(12), 1996, 2801.
106. Lode, H.N., Xiang, R., Dreier, T., Varki, N.M., Gillies, S.D., Reisfeld, R.A., Natural killer cell–mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91:5 (1998), 1706–1715.
107. Osenga, K.L., Hank, J.A., Albertini, M.R., Gan, J., Sternberg, A.G., Eickhoff, J., Seeger, R.C., Matthay, K.K., Reynolds, C.P., Twist, C., A phase I clinical trial of the hu14. 18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin. Cancer Res. 12:6 (2006), 1750–1759.
108. King, D.M., Albertini, M.R., Schalch, H., Hank, J.A., Gan, J., Surfus, J., Mahvi, D., Schiller, J.H., Warner, T., Kim, K., Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J. Clin. Oncol. 22:22 (2004), 4463–4473.
109. Shusterman, S., London, W.B., Gillies, S.D., Hank, J.A., Voss, S.D., Seeger, R.C., Reynolds, C.P., Kimball, J., Albertini, M.R., Wagner, B., Antitumor activity of hu14. 18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J. Clin. Oncol. 28:33 (2010), 4969–4975.
110. Albertini, M.R., Hank, J.A., Gadbaw, B., Kostlevy, J., Haldeman, J., Schalch, H., Gan, J., Kim, K., Eickhoff, J., Gillies, S.D., Phase II trial of hu14. 18-IL2 for patients with metastatic melanoma. Cancer Immunol. Immunother. 61:12 (2012), 2261–2271.
111. Yang, R.K., Kalogriopoulos, N.A., Rakhmilevich, A.L., Ranheim, E.A., Seo, S., Kim, K., Alderson, K.L., Gan, J., Reisfeld, R.A., Gillies, S.D., Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14. 18 antibody increases intratumoral CD8+ T and NK cells and improves survival. Cancer Immunol. Immunother. 62:8 (2013), 1303–1313.
112. Yang, R.K., Kalogriopoulos, N.A., Rakhmilevich, A.L., Ranheim, E.A., Seo, S., Kim, K., Alderson, K.L., Gan, J., Reisfeld, R.A., Gillies, S.D., Intratumoral hu14. 18–IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention. J. Immunol. 189:5 (2012), 2656–2664.
113. Aghebati-Maleki, L., Younesi, V., Jadidi-Niaragh, F., Baradaran, B., Majidi, J., Yousefi, M., Isolation and characterization of anti ROR1 single chain fragment variable antibodies using phage display technique. Hum. Antibodies 25:1–2 (2017), 57–63.
114. Carnemolla, B., Borsi, L., Balza, E., Castellani, P., Meazza, R., Berndt, A., Ferrini, S., Kosmehl, H., Neri, D., Zardi, L., Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99:5 (2002), 1659–1665.
115. Wagner, K., Schulz, P., Scholz, A., Wiedenmann, B., Menrad, A., The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. Clin. Cancer Res. 14:15 (2008), 4951–4960.
116. Wolf, S.F., Temple, P.A., Kobayashi, M., Young, D., Dicig, M., Lowe, L., Dzialo, R., Fitz, L., Ferenz, C., Hewick, R.M., Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J. Immunol. 146:9 (1991), 3074–3081.
117. Gubler, U., Chua, A.O., Schoenhaut, D.S., Dwyer, C.M., McComas, W., Motyka, R., Nabavi, N., Wolitzky, A.G., Quinn, P.M., Familletti, P.c., Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc. Natl. Acad. Sci. 88:10 (1991), 4143–4147.
118. Gately, M.K., Renzetti, L.M., Magram, J., Stern, A.S., Adorini, L., Gubler, U., Presky, D.H., The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16:1 (1998), 495–521.
119. Arenberg, D.A., Kunkel, S.L., Polverini, P.J., Morris, S.B., Burdick, M.D., Glass, M.C., Taub, D.T., Iannettoni, M.D., Whyte, R.I., Strieter, R.M., Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med. 184:3 (1996), 981–992.
120. Duda, D.G., Sunamura, M., Lozonschi, L., Kodama, T., Egawa, S.-i, Matsumoto, G., Shimamura, H., Shibuya, K., Takeda, K., Matsuno, S., Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res. 60:4 (2000), 1111–1116.
121. Mocellin, S., Wang, E., Marincola, F.M., Cytokines and immune response in the tumor microenvironment. J. Immunother. 24:5 (2001), 392–407.
122. Del Vecchio, M., Bajetta, E., Canova, S., Lotze, M., Wesa, A., Parmiani, G., Anichini, A., Interleukin-12: biological properties and clinical application. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 13:16 (2007), 4677–4685.
123. Colombo, M.P., Trinchieri, G., Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13:2 (2002), 155–168.
124. Leonard, J.P., Sherman, M.L., Fisher, G.L., Buchanan, L.J., Larsen, G., Atkins, M.B., Sosman, J.A., Dutcher, J.P., Vogelzang, N.J., Ryan, J.L., Effects of single-dose interleukin-12 exposure on interleukin-12–associated toxicity and interferon-γ production. Blood 90:7 (1997), 2541–2548.
125. Slamon, D., Studies of the HER-2/neu proto-oncogene in human breast cancer. Cancer Invest., 8(2), 1989 253-253.
126. Slamon, D., Clark, G., Wong, S., Levin, W., Ullrich, A., McGuire, W., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, NY) 235:4785 (1987), 177–182.
127. Halin, C., Gafner, V., Villani, M.E., Borsi, L., Berndt, A., Kosmehl, H., Zardi, L., Neri, D., Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor α. Cancer Res. 63:12 (2003), 3202–3210.
128. Halin, C., Rondini, S., Nilsson, F., Berndt, A., Kosmehl, H., Zardi, L., Neri, D., Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat. Biotechnol. 20:3 (2002), 264–269.
129. Midulla, M., Verma, R., Pignatelli, M., Ritter, M.A., Courtenay-Luck, N.S., George, A.J., Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells. Cancer Res. 60:1 (2000), 164–169.
130. Menrad, A., Menssen, H.D., ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin. Ther. Targets 9:3 (2005), 491–500.
131. Jakobisiak, M., Golab, J., Lasek, W., Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev. 22:2 (2011), 99–108.
132. Mac'Cheever, M.A., Twelve immunotherapy drugs that could cure cancers. Immunol. Rev. 222:1 (2008), 357–368.
133. Waldmann, T.A., The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6:8 (2006), 595–601.
134. Marks-Konczalik, J., Dubois, S., Losi, J.M., Sabzevari, H., Yamada, N., Feigenbaum, L., Waldmann, T.A., Tagaya, Y., IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc. Natl. Acad. Sci. 97:21 (2000), 11445–11450.
135. Berger, C., Berger, M., Hackman, R.C., Gough, M., Elliott, C., Jensen, M.C., Riddell, S.R., Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 114:12 (2009), 2417–2426.
136. Steel, J.C., Waldmann, T.A., Morris, J.C., Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci. 33:1 (2012), 35–41.
137. Dubois, S., Mariner, J., Waldmann, T.A., Tagaya, Y., IL-15Rα recycles and presents IL-15 In trans to neighboring cells. Immunity 17:5 (2002), 537–547.
138. Schluns, K.S., Stoklasek, T., Lefrançois, L., The roles of interleukin-15 receptor α: trans-presentation, receptor component, or both?. Int. J. Biochem. Cell Biol. 37:8 (2005), 1567–1571.
139. Stonier, S.W., Schluns, K.S., Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol. Lett. 127:2 (2010), 85–92.
140. Rubinstein, M.P., Kovar, M., Purton, J.F., Cho, J.-H., Boyman, O., Surh, C.D., Sprent, J., Converting IL-15 to a superagonist by binding to soluble IL-15Rα. Proc. Natl. Acad. Sci. 103:24 (2006), 9166–9171.
141. Elpek, K.G., Rubinstein, M.P., Bellemare-Pelletier, A., Goldrath, A.W., Turley, S.J., Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Rα complexes. Proc. Natl. Acad. Sci. 107:50 (2010), 21647–21652.
142. Bessard, A., Solé, V., Bouchaud, G., Quéméner, A., Jacques, Y., High antitumor activity of RLI, an interleukin-15 (IL-15)–IL-15 receptor α fusion protein, in metastatic melanoma and colorectal cancer. Mol. Cancer Ther. 8:9 (2009), 2736–2745.
143. Stoklasek, T.A., Schluns, K.S., Lefrançois, L., Combined IL-15/IL-15R(immunotherapy maximizes IL-15 activity in vivo. J. Immunol. 177:9 (2006), 6072–6080.
144. Dubois, S., Patel, H.J., Zhang, M., Waldmann, T.A., Müller, J.R., Preassociation of IL-15 with IL-15Rα-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44 high t cells and its antitumor action. J. Immunol. 180:4 (2008), 2099–2106.
145. Epardaud, M., Elpek, K.G., Rubinstein, M.P., Yonekura, A.-r., Bellemare-Pelletier, A., Bronson, R., Hamerman, J.A., Goldrath, A.W., Turley, S.J., Interleukin-15/interleukin-15Rα complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res. 68:8 (2008), 2972–2983.
146. Rückert, R., Herz, U., Paus, R., Ungureanu, D., Pohl, T., Renz, H., Bulfone-Paus, S., IL-15-IgG2b fusion protein accelerates and enhances a Th2 but not a Th1 immune response in vivo, while IL-2-IgG2b fusion protein inhibits both. Eur. J. Immunol. 28:10 (1998), 3312–3320.
147. Wei, X.-q., Orchardson, M., Gracie, J.A., Leung, B.P., Gao, B.-m., Guan, H., Niedbala, W., Paterson, G.K., McInnes, I.B., Liew, F.Y., The sushi domain of soluble IL-15 receptor α is essential for binding IL-15 and inhibiting inflammatory and allogenic responses in vitro and in vivo. J. Immunol. 167:1 (2001), 277–282.
148. Mortier, E., Quéméner, A., Vusio, P., Lorenzen, I., Boublik, Y., Grötzinger, J., Plet, A., Jacques, Y., Soluble interleukin-15 receptor α (IL-15Rα)-sushi as a selective and potent agonist of IL-15 action through IL-15Rβ/γ HYPERAGONIST IL-15· IL-15Rα FUSION PROTEINS. J. Biol. Chem. 281:3 (2006), 1612–1619.
149. Huntington, N.D., Alves, N.L., Legrand, N., Lim, A., Strick-Marchand, H., Mention, J.-J., Plet, A., Weijer, K., Jacques, Y., Becker, P.D., IL-15 transpresentation promotes both human T-cell reconstitution and T-cell–dependent antibody responses in vivo. Proc. Natl. Acad. Sci. 108:15 (2011), 6217–6222.
150. Farrar, M., Schreiber, R., The molecular cell biology of interferon-gamma and its receptor. Annu. Rev. Immunol., 11, 1993, 571.
151. Bach, E.A., Aguet, M., Schreiber, R.D., The IFNγ receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15:1 (1997), 563–591.
152. Windbichler, G., Hausmaninger, H., Stummvoll, W., Graf, A., Kainz, C., Lahodny, J., Denison, U., Müller-Holzner, E., Marth, C., Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br. J. Cancer, 82(6), 2000, 1138.
153. Marth, C., Windbichler, G., Hausmaninger, H., Petru, E., Estermann, K., Pelzer, A., Mueller-Holzner, E., Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int. J. Gynecol. Cancer 16:4 (2006), 1522–1528.
154. Xiang, J., Qi, Y., Luo, X., Liu, E., Recombinant bifunctional molecule FV/IFN-γ possesses the anti-tumor FV as well as the gamma interferon activities. Cancer Biother. Radiopharm. 8:4 (1993), 327–337.
155. Ebbinghaus, C., Ronca, R., Kaspar, M., Grabulovski, D., Berndt, A., Kosmehl, H., Zardi, L., Neri, D., Engineered vascular-targeting antibody-interferon-γ fusion protein for cancer therapy. Int. J. Cancer 116:2 (2005), 304–313.
156. List, T., Neri, D., Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin. Pharmacol.: Adv. Appl., 5, 2013, 29.
157. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 5:144 (2011), 646–674.
158. Zardi, L., Carnemolla, B., Siri, A., Petersen, T., Paolella, G., Sebastio, G., Baralle, F., Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J., 6(8), 1987, 2337.
159. Neri, D., Bicknell, R., Tumour vascular targeting. Nat. Rev. Cancer 5:6 (2005), 436–446.
160. D. Neri, H., Menssen, A., Menrad, C. Schliemann, Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart, Google Patents, 2016.
161. Carnemolla, B., Balza, E., Siri, A., Zardi, L., Nicotra, M.R., Bigotti, A., Natali, P.G., A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J. Cell Biol. 108:3 (1989), 1139–1148.
162. Kaczmarek, J., Castellani, P., Nicolo, G., Spina, B., Allemanni, G., Zardi, L., Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int. J. Cancer 59:1 (1994), 11–16.
163. Castellani, P., Viale, G., Dorcaratto, A., Nicolo, G., Kaczmarek, J., Querze, G., Zardi, L., The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer 59:5 (1994), 612–618.
164. Castellani, P., Borsi, L., Carnemolla, B., Biro, A., Dorcaratto, A., Viale, G.L., Neri, D., Zardi, L., Differentiation between high-and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am. J. Pathol. 161:5 (2002), 1695–1700.
165. Borsi, L., Balza, E., Bestagno, M., Castellani, P., Carnemolla, B., Biro, A., Leprini, A., Sepulveda, J., Burrone, O., Neri, D., Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int. J. Cancer 102:1 (2002), 75–85.
166. List, T., Neri, D., Biodistribution Studies with Tumor-targeting Bispecific Antibodies Reveal Selective Accumulation at the Tumor Site, MAbs. 2012, Taylor & Francis, 775–783.
167. Viti, F., Tarli, L., Giovannoni, L., Zardi, L., Neri, D., Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res. 59:2 (1999), 347–352.
168. Tarli, L., Balza, E., Viti, F., Borsi, L., Castellani, P., Berndorff, D., Dinkelborg, L., Neri, D., Zardi, L., A high-affinity human antibody that targets tumoral blood vessels. Blood 94:1 (1999), 192–198.
169. Demartis, S., Tarli, L., Borsi, L., Zardi, L., Neri, D., Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur. J. Nucl. Med. 28:4 (2001), 534–539.
170. Santimaria, M., Moscatelli, G., Viale, G.L., Giovannoni, L., Neri, G., Viti, F., Leprini, A., Borsi, L., Castellani, P., Zardi, L., Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res. 9:2 (2003), 571–579.